Novartis AGNVSNYSE
Loading
EBITDA Over TimeExpanding
Percentile Rank93
3Y CAGR+16.1%
5Y CAGR+6.0%
Studio
Year-over-Year Change

Earnings before interest, taxes, depreciation, and amortization

3Y CAGR
+16.1%/yr
vs -7.7%/yr prior
5Y CAGR
+6.0%/yr
Recent acceleration
Acceleration
+23.8pp
Accelerating
Percentile
P93
Near historical high
vs 5Y Ago
1.3x
Solid growth
Streak
3 yr
Consecutive growthExpanding
PeriodValueYoY Change
2025$22.99B+11.0%
2024$20.71B+13.5%
2023$18.25B+24.3%
2022$14.68B-52.5%
2021$30.91B+79.6%
2020$17.21B+10.2%
2019$15.62B-22.8%
2018$20.24B+38.7%
2017$14.59B+0.1%
2016$14.57B-